Real-world outcomes after switching to faricimab in previously treated neovascular age-related macular degeneration: longitudinal outcomes up to 24 months
Daniel Egger, Florian Amesbauer, Hamza Mohamed, Konstantin E Thiel, Reinhard Angermann, Sebastian M Waldstein · 2026
Read Real-world outcomes after switching to faricimab in previously treated neovascular age-related macular degeneration: longitudinal outcomes up to 24 months by Daniel Egger, Florian Amesbauer, Hamza Mohamed, Konstantin E Thiel, Reinhard Angermann, Sebastian M Waldstein (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13551942.txt.
Description
A 2026 study by Daniel Egger and five colleagues followed a drug switch in a serious eye disease. The disease is wet age-related macular degeneration. Some eyes stay active despite standard injections. Clinics switched 43 eyes from 38 patients to a newer drug, faricimab. All had failed to stretch visit gaps beyond eight weeks on older drugs. The team tracked vision, retinal thickness, and fluid for up to two years.
Vision held steady through follow-up, with no firm change at any visit. Retinal thickness fell and stayed lower. A pigment layer swelling also shrank over time. Fluid under the retina dropped at every check. The share of dry maculas rose from zero to about a quarter. Visit gaps lengthened from under six weeks before the switch.
Catalog record
| CREATOR | Daniel Egger, Florian Amesbauer, Hamza Mohamed, Konstantin E Thiel, Reinhard Angermann, Sebastian M Waldstein |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32177 |
| LICENSE | https://creativecommons.org/publicdomain/zero/1.0 |
| RIGHTS | CC0 |
| SOURCE | Europe PMC |